1. Scrip
  2. >>R&D

Chinese Biotechs Refuel AI Enthusiasm After DeepSeek Breakout

 
• By Dexter Jie Yan

In one sign of renewed interest in AI tools from Chinese biotechs, Harbour BioMed has linked with InSilico Medicine for antibody discovery. Meanwhile, Antengene and AIM Vaccine will use DeepSeek's AI technology to support drug and vaccine development.

More Chinese biotechs look to artificial intelligence after the DeepSeek hit. (Shutterstock)

Multiple Chinese biotechs appear to have renewed enthusiasm for the application of artificial intelligence (AI) to help discover and develop novel therapeutics and vaccines following the December breakout release of DeepSeek-R1, a homegrown open-source generative AI application that has taken the world by storm.

Key Takeaways
  • Chinese biotech Harbour BioMed and AI-assisted US firm InSilico Medicine have teamed up for the discovery of novel antibodies, in one sign of Chinese companies' renewed interest in AI tools.
  • In addition, Antengene will deploy the DeepSeek platform to assist in identifying new tumor antigens suitable for the development of novel T-cell engagers

While the AI-driven discovery of small molecules has been developing for years, Chinese biotech Harbour BioMed and InSilico Medicine, a US AI-assisted drug discovery venture with operations in Hong

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

More from Business

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.